A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 301–400 of 1,002
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 72
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 69
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 72
Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties
Tatarnikova, O. G., Орлов, М. А., & Bobkova, N. V. (2015) · Biochemistry (Moscow) · doi:10.1134/s000629791513012x · Cited by 69
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 59
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 63
Broadstock, M., Ballard, C., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 58
“Of concern, there was a trend towards a dose-dependent decrease in cognition with both secretase treatments, and an increase in target-based side effects [25,27].”
BackgroundGamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Morgan, K. M., Fischer, B. S., Lee, F. Y., Shah, J. J., Bertino, J. R., Rosenfeld, J., Singh, A., Khiabanian, H., & Pine, S. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0439 · Cited by 63
“GSIs were originally developed with the intent to treat Alzheimer's disease by decreasing the formation of beta-amyloid in the brain, though clinical trials failed due to high toxicity in this population and/or poor response (9, 10).”
BackgroundRecent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 72
Unravelling disparate roles of NOTCH in bladder cancer
Goriki, A., Seiler, R., Wyatt, A. W., Contreras‐Sanz, A., Bhat, A. V., Matsubara, A., Hayashi, T., & Black, P. C. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0005-1 · Cited by 65
Chen, A. C., Kim, S., Shepardson, N., Patel, S., Hong, S., & Selkoe, D. J. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201502001 · Cited by 62
“…of the α–γ-secretase complex The TSP AN web has been extensively implicated in the stability and activity of A10 and separately for γ-secretase (Arduise et al., 2008; Wakabayashi et al., 2009; Xu et al., 2009; Dunn et al., 2010; Dornier et al., 2012; Haining et al., 2012; Prox et al., 2012).”
BackgroundQu, L., Li, S., Ji, L., Luo, S., Ding, M., Yin, F., Wang, C., Luo, H., Lu, D., Liu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113889 · Cited by 61
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.022 · Cited by 66
“However, the g-secretase inhibitors were found to cause severe side effects in late-stage clinical trials, presumably due to the large number of substrates that this enzyme recognizes.(34,35) In this study we aimed to specifically target presenilin 1, the catalytic subunit of the g-secretase complex, at the genetic le…”
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 62
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 59
The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia
Tasaki, S., Gaiteri, C., Mostafavi, S., De Jager, P. L., & Bennett, D. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00699 · Cited by 59
Taylor, M. K., Swerdlow, R. H., & Sullivan, D. K. (2019) · Nutrients · doi:10.3390/nu11081910 · Cited by 65
“After involvement in a research study of an investigational AD drug now known to have caused patients to decline rapidly [177], the patient’s disposition deteriorated.”
BackgroundPérez‐González, R., Kim, Y., Miller, C., Pacheco‐Quinto, J., Eckman, E. A., & Levy, E. (2020) · The FASEB Journal · doi:10.1096/fj.202000823r · Cited by 52
Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer’s Disease
Zhu, L., Xu, L., Wu, X., Deng, F., Ma, R., Liu, Y., Huang, F., & Shi, L. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00257 · Cited by 57
Pasternak, J. J., & Lanier, W. L. (2009) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000048 · Cited by 62
Alzheimer’s Disease: Advances in Drug Development
Piton, M., Hirtz, C., Desmetz, C., Milhau, J., Lajoix, A. D., Bennys, K., Lehmann, S., & Gabelle, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180145 · Cited by 60
Espay, A. J., & Lang, A. E. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181465 · Cited by 61
Al-kuraishy, H., Jabir, M., Al-Gareeb, A., Albuhadily, A. K., Albukhaty, S., Sulaiman, G., & Batiha, G. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102119 · Cited by 53
Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease
Egorova, P. A., Александровна, П. Е., & Борисович, Б. И. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.03.010 · Cited by 64
Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ
Hurtado, C., Safarova, A. G., Smith, M. P., Chung, R., Bruyneel, A. A. N., Gomez‐Galeno, J., Oswald, F., Larson, C. J., Cashman, J. R., Ruiz‐Lozano, P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46948-5 · Cited by 65
Mechanisms of neurodegeneration — Insights from familial Alzheimer’s disease
Chávez-Gutiérrez, L., & Szaruga, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.03.005 · Cited by 58
Richter, L. R., Wan, Q., Wen, D., Zhang, Y., Yu, J., Kang, J. K., Zhu, C., McKinnon, E. L., Gu, Z., Qiang, L., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c01007 · Cited by 59
Turning the tide on Alzheimer’s disease: modulation of γ-secretase
Luo, J. E., & Li, Y.-M. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00738-7 · Cited by 59
Pan, X., Chen, Z., Fei, G., Pan, S., Bao, W., Ren, S., Guan, Y., & Zhong, C. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0067-0 · Cited by 59
Zhou, Y., Wang, Z., Li, W., Hong, H., Chen, J., Tian, Y., & Liu, Z. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26700 · Cited by 59
RetractedSiddappaji, K. K., & Gopal, S. (2021) · AIMS neuroscience · doi:10.3934/neuroscience.2021020 · Cited by 66
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 65
Vallés, A. S., Borroni, M. V., & Barrantes, F. J. (2014) · CNS Drugs · doi:10.1007/s40263-014-0201-3 · Cited by 66
“Most of the compounds effectively reduce cerebrospinal Ab-peptide levels and amyloid senile plaques but the expected clinical outcome, cognitive improvement, is not observed [47–49].”
BackgroundMoonga, I., Niccolini, F., Wilson, H., Pagano, G., Politis, M., & Initiative, T. A. D. N. (2017) · European Journal of Neurology · doi:10.1111/ene.13374 · Cited by 61
Scarpa, M., Hesse, S., & Bradley, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.003 · Cited by 62
Molecular mechanism of intramembrane proteolysis by γ-secretase
Tomita, T. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvu049 · Cited by 58
Delre, P., Caporuscio, F., Saviano, M., & Mangiatordi, G. F. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.594009 · Cited by 60
“Semagacestat is a drug in phase III clinical trials for Alzheimer's disease (AD) treatment and its activity is related to the inhibition of a multi-subunit protease complex named γ-secretase (Doody et al., 2013).”
BackgroundParkinson’s disease: From human genetics to clinical trials
van der Brug, M. P., Singleton, A., Gasser, T., & Lewis, P. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8280 · Cited by 62
Physiological and pathological roles of the γ-secretase complex
Carroll, C. M., & Li, Y.-M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.019 · Cited by 53
Calibrating Longitudinal Cognition in Alzheimer's Disease Across Diverse Test Batteries and Datasets
Gross, A. L., Sherva, R., Mukherjee, S., Newhouse, S., Kauwe, J. S. K., Munsie, L. M., Waterston, L. B., Bennett, D. A., Jones, R. N., Green, R. C., et al. (2014) · Neuroepidemiology · doi:10.1159/000367970 · Cited by 56
Molecular Aspects of Head and Neck Cancer Therapy
Puram, S. V., & Rocco, J. W. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.07.003 · Cited by 57
“In addition, inhibition of NOTCH activation has been associated with an increased risk of cutaneous SCC, with a recent phase III trial with the gamma-secretase inhibitor semagacestat halted due to an increased rate of cutaneous SCC in the treatment arm compared to placebo (25).”
BackgroundDoes Notch play a tumor suppressor role across diverse squamous cell carcinomas?
Zhang, M., Biswas, S., Qin, X., Gong, W., Deng, W., & Yu, H. (2016) · Cancer Medicine · doi:10.1002/cam4.731 · Cited by 60
“A recent clinical Phase III trial of Semagacestat, a γsecretase/Notch inhibitor, was halted in part because of an increased risk of skin cancers compared with those in the placebo arm [31].”
Pullamsetti, S. S., Perros, F., Chelladurai, P., Yuan, J. X. ‐., & Stenmark, K. R. (2016) · Pulmonary Circulation · doi:10.1086/688908 · Cited by 61
Tseng, L.-Y., Huang, S., Peng, L., Chen, L., & Hsiao, F. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00801-9 · Cited by 120
“However, new therapeutic agents inhibiting gamma secretase have not shown significant effects on dementia compared to placebo [44, 45].”
BackgroundMachine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer’s Disease
Ezzati, A., Initiative, A. D. N., & Lipton, R. B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190822 · Cited by 60
“• Genomics: ApoE4 status • Cognitive scores: MMSE, ADAS-cog • Clinical information: Geriatric depression scale (GDS) [19] • MRI volumetrics: left hippocampal volume, right Hippocampal volume, Ventricular volume (sum of lateral and third ventricles), and total brain volume.”
Notch signaling in cancer: Complexity and challenges on the path to clinical translation
Ferreira, A. P. A., & Aster, J. C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.008 · Cited by 56
Systems biology of neurodegenerative diseases
Wood, L. B., Winslow, A. R., & Strasser, S. D. (2015) · Integrative Biology · doi:10.1039/c5ib00031a · Cited by 53
The Emerging Role of Tetraspanins in the Proteolytic Processing of the Amyloid Precursor Protein
Seipold, L., & Saftig, P. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00149 · Cited by 52
“However, most therapeutic approaches targeting γ-secretase activity were accompanied by severe side effects, like skin cancer development, gastrointestinal toxicity and infections (Doody et al., 2013), due to the physiological role of its substrates, for example Notch1 (Haapasalo and Kovacs, 2011).”
BackgroundThe Promises and Challenges of Erythropoietin for Treatment of Alzheimer’s Disease
Sun, J., Martin, J. M., Vanderpoel, V., & Sumbria, R. K. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08524-y · Cited by 57
Alzheimer's disease: Only prevention makes sense
Viña, J., & Sanz‐Ros, J. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13005 · Cited by 57
“Moreover, treatment was associated with more adverse events, including skin cancers.(5) Another trial using tramiprosate, an Aβ aggregation inhibitor, offered some hope in that hippocampal volume loss was diminished when compared with placebo, but unfortunately, no significant effects on the primary outcome, the loss…”
BackgroundThe Use of Antimicrobial and Antiviral Drugs in Alzheimer’s Disease
Iqbal, U., Zeng, E., & Pasinetti, G. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144920 · Cited by 57
Venkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 56
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 59
γ-Secretase and its modulators: Twenty years and beyond
Xia, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.011 · Cited by 54
“clinical measures of cognition and the ability to perform activities of daily living [48,49].”
BackgroundImpact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12463 · Cited by 54
Alexander, C., Parsaee, A., & Vasefi, M. (2023) · Biology · doi:10.3390/biology12111453 · Cited by 62
Treating Alzheimer’s disease using nanoparticle-mediated drug delivery strategies/systems
Roghani, A. K., Garcia, R. I., Roghani, A., Reddy, A. P., Khemka, S., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102291 · Cited by 57
Sherva, R., Gross, A., Mukherjee, S., Koesterer, R., Amouyel, P., Bellenguez, C., Dufouil, C., Bennett, D. A., Chibnik, L., Cruchaga, C., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12106 · Cited by 54
Modeling neurological disorders using brain organoids
Zhang, D. Y., Song, H., & Ming, G. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.026 · Cited by 54
NAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal
Kuruva, C. S., & Reddy, P. H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.010 · Cited by 49
Ma, J., Gao, Y., Jiang, L., Chao, F.-L., Huang, W., Zhou, C.-N., Tang, W., Zhang, L., Huang, C.-X., Zhang, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15398 · Cited by 51
Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer’s Disease
Kwak, K.-A., Lee, S., Yang, J.-Y., & Park, Y. (2018) · Stem Cells International · doi:10.1155/2018/6392986 · Cited by 54
Buechler, J., & Salinas, P. C. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00038 · Cited by 51
Towards universal therapeutics for memory disorders
Sun, M., Nelson, T. J., & Alkon, D. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.004 · Cited by 54
Proteolytic processing of Neuregulin-1
Willem, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.07.003 · Cited by 57
Aizawa, S., Okamoto, T., Sugiyama, Y., Kouwaki, T., Ito, A., Suzuki, T., Ono, C., Fukuhara, T., Yamamoto, M., Okochi, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11379 · Cited by 52
“The serum concentrations of b-amyloid 40 and 42 were quantified using a Human/Rat b-Amyloid (40) ELISA kit (WAKO) and Human/Rat b-Amyloid (42) ELISA kit (WAKO).”
MethodLu, Y., Wan, J., Yang, Z., Lei, X., Niu, Q., Jiang, L., Passtoors, W. M., Zang, A., Fraering, P. C., & Wu, F. (2016) · The FASEB Journal · doi:10.1096/fj.201600702r · Cited by 60
Yang, J., Hu, C., Guo, N., Dutta, J., Vaina, L. M., Johnson, K. A., Sepulcre, J., Fakhri, G. E., & Li, Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-13339-7 · Cited by 52
Is Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer's Disease?
Wang, S., Mims, P. N., Roman, R. J., & Fan, F. (2016) · PubMed · Cited by 63
Unraveling the complexity of γ-secretase
Wolfe, M. S. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.005 · Cited by 55
“Beyond development, inhibition of γ-secretase in human clinical trials also resulted in severe toxic effects such as gastrointestinal bleeding, immunosuppression, and skin lesions, likewise due to inhibition of Notch signaling needed for regulation of cell differentiation [94, 95].”
BackgroundRecent developments of small molecule γ-secretase modulators for Alzheimer's disease
Mekala, S., Nelson, G., & Li, Y.-M. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00196a · Cited by 49
Bi, D., Yao, L., Lin, Z., Chi, L., Li, H., Xu, H. Y., Du, X., Liu, Q., Hu, Z., Lu, J., et al. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117124 · Cited by 53
Inactivation of γ‐secretases leads to accumulation of substrates and non‐Alzheimer neurodegeneration
Acx, H., Serneels, L., Radaelli, E., Muyldermans, S., Vincke, C., Pepermans, E., Müller, U., Chávez‐Gutiérrez, L., & De Strooper, B. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707561 · Cited by 49
“The recent failures of broad spectrum c -secretase inhibitors in the clinic (Doody et al , 2013; Coric et al , 2015) dramatically illustrates our lack of basic knowledge of the c -secretases (De Strooper, 2014).”
Yuan, C., Guo, X., Zhou, Q., Du, F., Jiang, W., Zhou, X., Liu, P., Chi, T., Ji, X., Gao, J., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.028 · Cited by 53
L-Norvaline, a new therapeutic agent against Alzheimer’s disease
Polis, B., Srikanth, K. D., Gurevich, V., Gil-Henn, H., & Samson, A. O. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.255980 · Cited by 52
“Moreover, some trials were terminated because of adverse effects (Lahiri et al., 2014; Doody et al., 2013).”
BackgroundQi, L., Liu, S., Liu, Y.-C., Li, P., & Xu, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115559 · Cited by 54
“Despite its inhibition of Aβ production, semagacestat did not improve the cognitive status of patients, and there was even significant worsening of functional ability at higher doses [50].”
BackgroundWhat lessons can be learned from failed Alzheimer’s disease trials?
Toyn, J. H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1034690 · Cited by 53
Nakano, M., Kubota, K., Hashizume, S., Kobayashi, E., Chikenji, T., Saito, Y., & Fujimiya, M. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100149 · Cited by 53
Brendel, M., Jaworska, A., Herms, J., Trambauer, J., Rötzer, C., Gildehaus, F.-J., Carlsen, J., Cumming, P., Bylund, J., Luebbers, T., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.74 · Cited by 50
Hall, A., & Patel, T. R. (2014) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-63380-4.00003-2 · Cited by 49
Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology
Voyle, N., Baker, D., Burnham, S. C., Covin, A., Zhang, Z., Sangurdekar, D. P., Tan Hehir, C. A., Bazenet, C., Lovestone, S., Kiddle, S., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150020 · Cited by 50
“∗Correspondence to: Nicola Voyle and Richard J.B. Dobson, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychology, Psychiatry and Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.”
Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's disease
Somavarapu, A. K., & Kepp, K. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13535 · Cited by 53
Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606
Wagner, S. L., Rynearson, K. D., Duddy, S. K., Zhang, C., Nguyen, P. D., Becker, A., Vo, U., Masliah, D., Monte, L., Klee, J. B., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240861 · Cited by 49
Membrane Dynamics of γ-Secretase Provides a Molecular Basis for β-Amyloid Binding and Processing
Somavarapu, A. K., & Kepp, K. P. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00208 · Cited by 51
Substrate recognition and processing by γ-secretase
Wolfe, M. S. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.07.004 · Cited by 53
“Notch signaling in cell differentiation is also critical in adult organisms, as γ-secretase inhibitors developed for Alzheimer’s disease resulted in effects consistent with Notch deficiencies: immunosuppression, gastrointestinal toxicity, and skin lesions (Coric et al., 2015; Doody et al., 2013).”
BackgroundFlavonoid-Based Nanomedicines in Alzheimer’s Disease Therapeutics: Promises Made, a Long Way To Go
Prasanna, P., & Upadhyay, A. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00224 · Cited by 53
Barbera, L. L., Nobili, A., Cauzzi, E., Paoletti, I., Federici, M., Saba, L., Giacomet, C., Marino, R., Krashia, P., Melone, M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00580-6 · Cited by 50
Soares, H. D., Gasior, M., Toyn, J. H., Wang, J.-S., Hong, Q., Berisha, F., Furlong, M. T., Raybon, J., Lentz, K. A., Sweeney, F., et al. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232256 · Cited by 46
“…York, NY) [(2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]5,5,5-trifluoropentanamide] resulted in Notch-related nonmelanoma skin cancers and/or progression and worsening of cognitive measures (Fleisher et al., 2008; Coric et al., 2012; Doody et al., 2013).”
Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease
Zhu, H., Xue, X., Wang, E., Wallack, M., Na, H., Hooker, J. M., Kowall, N. W., Tao, Q., Stein, T. D., Wolozin, B. L., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.030 · Cited by 51
“The pathophysiology of AD is clearly pleitotropic, yet most attempts at disease-modification target a single component of AD pathology (Chiang and Koo, 2014; Doody et al., 2013; Imbimbo et al., 2012).”
BackgroundTaming the Notch Transcriptional Regulator for Cancer Therapy
Tamagnone, L., Zacchigna, S., & Rehman, M. (2018) · Molecules · doi:10.3390/molecules23020431 · Cited by 49
“Indeed, in some instances, GSI therapy was found to aggravate skin cancer [93,94].”
BackgroundNPT088 reduces both amyloid‐β and tau pathologies in transgenic mice
Levenson, J. M., Schroeter, S., Carroll, J. C., Cullen, V., Asp, E., Proschitsky, M., Chung, C. H. ‐., Gilead, S., Nadeem, M., Dodiya, H. B., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.004 · Cited by 47
Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies
Arbez‐Gindre, C., Steele, B. R., & Micha‐Screttas, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030898 · Cited by 49
“Secretase inhibitors have be n developed and tested with the aim of sup res ing the formation of Aβ, but the results have not be n fully convincing [19,20].”
BackgroundImplications of the Approval of Lecanemab for Alzheimer Disease Patient Care
Knopman, D. S., & Hershey, L. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207438 · Cited by 51
Hasegawa, H., Liu, L., Tooyama, I., Murayama, S., & Nishimura, M. (2014) · Nature Communications · doi:10.1038/ncomms4917 · Cited by 48
Calcium Signaling Deficits in Glia and Autophagic Pathways Contributing to Neurodegenerative Disease
Mustaly-Kalimi, S., Littlefield, A. M., & Stutzmann, G. E. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7266 · Cited by 45
Dysfunctional γ-Secretase in Familial Alzheimer’s Disease
Wolfe, M. S. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2511-1 · Cited by 51
Cao, L., Wang, Z., & Wan, W. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00417 · Cited by 50
Kawanishi, S., Takata, K., Itezono, S., Nagayama, H., Konoya, S., Chisaki, Y., Toda, Y., Nakata, S., Yano, Y., Kitamura, Y., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170994 · Cited by 49
Brewer, G. J., Herrera, R. A., Philipp, S., Sosna, J., Reyes‐Ruiz, J. M., & Glabe, C. G. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190835 · Cited by 49
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.